Literature DB >> 26893397

Might haplo "be the (better) match"?

Jennifer A Kanakry1, Leo Luznik2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26893397      PMCID： PMC4760085          DOI： 10.1182/blood-2016-01-689042

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors:  Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal:  Ther Adv Hematol       Date:  2015-12

2.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Jennifer A Kanakry; Margaret M Showel; Hua-Ling Tsai; Javier Bolaños-Meade; Gary L Rosner; Christopher G Kanakry; Karlo Perica; Heather J Symons; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; Keith W Pratz; Gabrielle T Prince; Amy E Dezern; Ivana Gojo; William H Matsui; Ivan Borrello; Michael A McDevitt; Lode J Swinnen; B Douglas Smith; Mark J Levis; Richard F Ambinder; Leo Luznik; Richard J Jones; Ephraim J Fuchs; Yvette L Kasamon
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

3.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.

Authors:  C Anasetti; P G Beatty; R Storb; P J Martin; M Mori; J E Sanders; E D Thomas; J A Hansen
Journal:  Hum Immunol       Date:  1990-10       Impact factor: 2.850

4.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

Authors:  Stefan O Ciurea; Mei-Jie Zhang; Andrea A Bacigalupo; Asad Bashey; Frederick R Appelbaum; Omar S Aljitawi; Philippe Armand; Joseph H Antin; Junfang Chen; Steven M Devine; Daniel H Fowler; Leo Luznik; Ryotaro Nakamura; Paul V O'Donnell; Miguel-Angel Perales; Sai Ravi Pingali; David L Porter; Marcie R Riches; Olle T H Ringdén; Vanderson Rocha; Ravi Vij; Daniel J Weisdorf; Richard E Champlin; Mary M Horowitz; Ephraim J Fuchs; Mary Eapen
Journal:  Blood       Date:  2015-06-30       Impact factor: 22.113

5.  Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

Authors:  Jennifer A Kanakry; Christopher D Gocke; Javier Bolaños-Meade; Douglas E Gladstone; Lode J Swinnen; Amanda L Blackford; Ephraim J Fuchs; Carol Ann Huff; Ivan Borrello; William H Matsui; Robert A Brodsky; Gary L Rosner; Satish Shanbhag; Leo Luznik; Richard J Jones; Richard F Ambinder; Yvette L Kasamon
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

6.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

Authors:  Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

Review 7.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675

8.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Authors:  Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

9.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

10.  Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Authors:  Abraham S Kanate; Alberto Mussetti; Mohamed A Kharfan-Dabaja; Kwang W Ahn; Alyssa DiGilio; Amer Beitinjaneh; Saurabh Chhabra; Timothy S Fenske; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark Hertzberg; Evgeny Klyuchnikov; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Andrew Rezvani; Marcie Riches; Ayman Saad; Shimon Slavin; Sonali M Smith; Anna Sureda; Jean Yared; Stefan Ciurea; Philippe Armand; Rachel Salit; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113
  10 in total
  2 in total

Review 1.  Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?

Authors:  Satish Shanbhag; Nina Wagner-Johnston; Richard F Ambinder; Richard J Jones
Journal:  Curr Oncol Rep       Date:  2019-06-10       Impact factor: 5.075

2.  Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review.

Authors:  Vivek S Radhakrishnan; Rajat Bajaj; Vasundhara Raina; Jeevan Kumar; Saurabh J Bhave; Reghu K Sukumaran Nair; Arijit Nag; Indu Arun; Lateef Zameer; Debdeep Dey; Neeraj Arora; Mayur Parihar; Jayanta Das; Rimpa B Achari; Deepak K Mishra; Mammen Chandy; Reena Nair
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.